Literature DB >> 3306386

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

P C de Groen, A J Aksamit, J Rakela, G S Forbes, R A Krom.   

Abstract

We describe severe central nervous system (CNS) toxicity, manifested by confusion, cortical blindness, quadriplegia, seizures, and coma, associated with cyclosporine treatment in three patients undergoing liver transplantation. CT and magnetic resonance studies disclosed a severe, diffuse disorder of the white matter. All side effects and radiographic findings were reversed with discontinuation or a reduction in the dose of cyclosporine. We also observed an inverse association between CNS side effects and total serum cholesterol levels after transplantation. A retrospective analysis of 54 liver transplantations performed in 48 patients revealed that 13 patients had symptoms of CNS toxicity associated with the use of cyclosporine. These patients' total serum cholesterol levels in the first week after transplantation were reduced as compared with those in patients without symptoms (mean +/- SE, 94 +/- 4 mg per deciliter vs. 132 +/- 6, or 2.44 +/- 0.10 mmol per liter vs. 3.43 +/- 0.16). We conclude that cyclosporine therapy for immunosuppression in liver transplantation may cause a syndrome of encephalopathy, seizures, and white-matter changes and that this is most likely to occur in patients with low total serum cholesterol levels after transplantation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306386     DOI: 10.1056/NEJM198710013171404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  81 in total

1.  Medication errors in paediatrics: a case report and systematic review of risk factors.

Authors:  O Diav-Citrin; S Ratnapalan; M Grouhi; C Roifman; G Koren
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

3.  Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Authors:  Sara Lewin; Fernando S Velayos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-09

4.  Cyclosporin for refractory ulcerative colitis.

Authors:  C G Loftus; E V Loftus; W J Sandborn
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

5.  Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.

Authors:  Tsuyoshi Miyakawa; Lorene M Leiter; David J Gerber; Raul R Gainetdinov; Tatyana D Sotnikova; Hongkui Zeng; Marc G Caron; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

Review 6.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

7.  [Case of inflammatory vasculopathy and encephalopathy caused by treatment with tacrolimus].

Authors:  Adrian Ringelstein; Katja Bongs; Burkhard Sorge-Hädicke; Peter Berlit
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

Review 8.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

9.  Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury.

Authors:  Patrick G Sullivan; Andrea H Sebastian; Edward D Hall
Journal:  J Neurotrauma       Date:  2011-02-02       Impact factor: 5.269

10.  Progressive visual deterioration leading to blindness after pediatric heart transplantation.

Authors:  K O Schowengerdt; R J Gajarski; S Denfield
Journal:  Tex Heart Inst J       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.